Esperion Reports Third Quarter 2023 Financial Results
November 07, 2023 06:00 ET
|
Esperion Therapeutics, Inc.
– Q3 U.S. Net Product Revenue Grew 45% Y/Y to $20.3 Million; Q3 Total Revenue Grew 79% Y/Y to $34.0 Million – – Q3 Retail Prescription Equivalents Grew 33% Y/Y and 8% Q/Q, Demonstrating Sustained...
Esperion to Participate in Jefferies London Healthcare Conference
October 31, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the Jefferies London Healthcare Conference. Sheldon Koenig, President and Chief...
Esperion to Report Third Quarter 2023 Financial Results on November 7
October 24, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2023 financial results before the market opens on Tuesday, November 7, 2023....
American College of Cardiology Program to Increase Cholesterol Screenings
September 12, 2023 10:15 ET
|
Esperion Therapeutics, Inc.; The American College of Cardiology
Quality Improvement and Education Program sponsored by Amgen, Esperion to improve adherence to guideline recommendations for managing LDL WASHINGTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The American...
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig,...
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
August 26, 2023 11:00 ET
|
Esperion Therapeutics, Inc.
– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 – – In an analysis of patients with diabetes, bempedoic acid shows 17%...
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
August 11, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced two oral presentations to take place in the Late-Breaking Science Session entitled “Clinical trial updates...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 08, 2023 16:15 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 8, 2023, the Company granted five new employees 14,000 restricted stock units (RSUs) under...
Esperion Reports Second Quarter 2023 Financial Results
August 01, 2023 06:00 ET
|
Esperion Therapeutics, Inc.
– Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million – – Q2 Retail Prescription Equivalents Grew 26% Y/Y; Q2 New to Brand Prescriptions Grew 28% Q/Q – – Submitted Applications for Expanded...
Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
July 24, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the BTIG Virtual Biotechnology Conference 2023. Ben Halladay, Chief Financial...